NextBio

Help
Description: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem]
Drug Type: Small Molecule; Nutraceutical; Approved; Investigational
Pharmacology: Niacin and niacinamide are indicated for prevention and treatment of vitamin B3 deficiency states. Vitamin B3 (Niacin) also acts to reduce LDL cholesterol, triglycerides, and HDL cholesterol. The magnitude of individual lipid and lipoprotein responses may be influenced by the severity and type of underlying lipid abnormality. The increase in total HDL is associated with a shift in the distribution of HDL subfractions (as defined by ultra-centrifugation) with an increase in the HDL2:HDL3 ratio and an increase in apolipoprotein A-I content. Vitamin B3 (Niacin) treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions, and of lipoprotein-a, a variant form of LDL independently associated with coronary risk.
Mechanism of Action: Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.
Indication: For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Half Life: 20-45 minutes.
View Complete Description




Individual Studies
  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…

  • Liver Pharmacology and Xenobiotic Response Repertoire

    Rattus norvegicus Rattus norvegicus | RNA Expression   RNA Expression

    A definition of RNA expression changes that correlate with liver response programs and an understanding of the similarities and differences in responses to different classes of chemicals would aid in new chemical or drug characterization and add to our understanding of liver biology.

    Authors: Natsoulis G, Pearson CI, Gollub J et al.

    Organization: Iconix Biosciences 325 E. Middlefield Rd…

View All Individual Studies

Thought leaders and organizations working on research involving niaspan.

  • Stefan Offermanns
  • Janet E Digby
  • Robin P Choudhury
  • Ning Ren
  • Kang Cheng
  • Merck
  • Kos Pharmaceuticals
  • University of Pennsylvania
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Palo Alto Medical Foundation
  • University of Heidelberg
  • University of Oxford
  • Merck Research Laboratories
  • Duke University Medical Center
  • Philipps-Universität Marburg

Clinical Trials | 372 trials

Help for Clinical Trials View All

Community

Help for Community
  • No NextBio users were found for “niaspan”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

  • No NextBio groups were found for “niaspan”.
    Be the first to start a group and share your interests with others within the NextBio community.